Once in a blue moon, a lawmaker publicly admits he regrets how he voted. Those of us present at Tuesday’s hearing in the Kansas House Health & Human Services committee witnessed such a concession.
The focus of the hearing was the status report on the Midwest Stem Cell Therapy Center (MSCTC), given primarily by Board advisor, Dr. David Prentice and the Director, Dr. Buddhadeb Dawn. The room was packed and the presentation was positively uplifting.
Gov. Sam Brownback, along with the Kansas Legislature, had approved the formation of the MSCTC in 2013 to be housed at the University of Kansas Medical Center in Kansas City. The Center is designed to serve as a regional hub of stem cell therapy, research, and education as well as an engine for increased processing of ethically-derived, “adult” stem cells (ASCs) for patient use.
There are numerous kinds of ASCs derived from different human tissues (see graphic). The point is that no ASCs require the destruction of human embryos.
In 2013, those paying careful attention to the stem cell issue realized the overblown expectations about the usefulness of stem cells derived from human embryos. Yet state Rep. John Wilson (D-Lawrence) was still unconvinced of the need to fund a patient-centered medical center using only non-embryonic stem cells. He voted against the measure, although the MSCTC passed.
On Tuesday, during the Q&A period, Wilson congratulated the Center for its success and acknowledged that he regretted voting against its creation. KFL later thanked Wilson for his remarks and joined him in his enthusiasm for the Center.
ADULT STEM CELL PROJECTS
Dr. Prentice, a native Kansan and frequent expert testifying on bioethical issues at the Kansas Statehouse, described ASC therapies as the “gold standard” in regenerative medicine, with over 1.5 million people having been treated to date, world-wide.
His presentation examined the real patients who are benefitting from the current therapies offered at the MSCTC, such as 300 patients annually receiving stem cells in collaboration with the KU Cancer Center.
Prentice detailed some specific projects already underway, some in pre-clinical research phase, and others in planning stages. They include numerous new and innovative uses for ASCs targeting the brain, heart, spinal cord, liver, and joints.
Of particular interest is the groundbreaking direction MSCTC is taking on “graft-versus-host” disease, which can be a serious complication for some bone marrow adult stem cell transplants. Graft-versus-host is a problem in which stem cells not derived from the patient are introduced into the patient to replace those lost through chemo/radiation, but the cells begin to attack the new “host” as foreign.
MSCTC’s director, cardiologist Dr. Dawn, is described by Prentice as one of the world leaders in cardiac repair technologies. With Dr. Dawn and other specialists at the Center, patients with severe heart ailments– formerly “without hope”– are given hope with adult stem cells.
Director Dawn pointed proudly to the Center’s accomplishments in a mere 3 ½ years, and described continuing efforts to collaborate with other scientists and private companies as well as develop methods and products that can be patented.
The fifth MSCTC annual conference is scheduled for September 15-16. Details about it and the Center can be found at http://www.kumc.edu/msctc.html.
The Midwest Stem Cell Therapy Center, committed to advancing the use of ethical science, is proving itself to be everything we hoped for.